UCB (OTCMKTS:UCBJY) Upgraded by Zacks Research to "Strong-Buy" Rating

Key Points

• Zacks Research upgraded UCB from a "hold" to a Strong-Buy, Wolfe Research also raised its rating to Strong-Buy, and three analysts now rate the stock as Strong Buy, leaving the consensus rating at Strong Buy.
• Shares opened at $156.58 and are trading near their 1-year high ($168.76) with a 50-day/200-day moving average of $153.41/$145.96, indicating recent price strength.
• UCB is a Belgium-based global biopharmaceutical company focused on neurology and immunology, with key marketed medicines including CIMZIA, VIMPAT, and NEUPRO.

UCB (OTCMKTS:UCBJY - Get Free Report) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a research report issued on Tuesday,Zacks.com reports.

Separately, Wolfe Research upgraded shares of UCB to a "strong-buy" rating in a research note on Monday, February 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, According to MarketBeat, the company presently has an average rating of "Strong Buy".

UCB Stock Performance

OTCMKTS:UCBJY opened at $156.58 on Tuesday. UCB has a 1-year low of $76.52 and a 1-year high of $168.76. The company's fifty day moving average price is $153.41 and its 200-day moving average price is $145.96. The company has a current ratio of 1.38, a quick ratio of 1.04 and a debt-to-equity ratio of 0.20.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson's disease, rheumatoid arthritis and Crohn's disease.

The company's commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson's disease and restless legs syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.